Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ALNY is in the long-term up 377% in 14 years.
Description: Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-CC5 for the treatment of complement-mediated diseases; ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCS for the treatment of hypercholesterolemia; ALN-AAT for the treatment of AAT deficiency liver disease; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other programs. The company?s partner-based product development clinical and pre-clinical programs comprise ALN-RSV01 for the treatment of respiratory syncytial virus infection; ALN-VSP for the treatment of liver
|Shares Outstanding||EPS||-4.83||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||154.11%||Sales Growth - Q/Q||-22.82%||P/E||-15.75|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-9.84%||ROE||-10.71%||ROI|
|Current Ratio||13.51||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.05|
|Gross Margin||Operating Margin||-309.32%||Net Profit Margin||-263.44%||Dividend Payout Ratio|
|Cash From Financing Activities||598.98 M||Cash From Investing Activities||-341.33 M||Cash From Operating Activities||-26.25 M||Gross Profit|
|Net Profit||-50.78 M||Operating Profit||-52.22 M||Total Assets||1.63 B||Total Current Assets||1.09 B|
|Total Current Liabilities||80.69 M||Total Debt||Total Liabilities||132.28 M||Total Revenue||18.54 M|
|High 52 week||148.54||Low 52 week||65.07||Last close||73.34||Last change||0.91%|
|RSI||28.58||Average true range||5.13||Beta||1.23||Volume||734.61 K|
|Simple moving average 20 days||-3.14%||Simple moving average 50 days||-10.23%||Simple moving average 200 days||-27.17%|
|Performance Week||5.72%||Performance Month||0.47%||Performance Quart||-24.29%||Performance Half||-26.65%|
|Performance Year||-44.58%||Performance Year-to-date||-42.27%||Volatility daily||4.85%||Volatility weekly||10.84%|
|Volatility monthly||22.22%||Volatility yearly||76.97%||Relative Volume||208.92%||Average Volume||940.78 K|
|New High||New Low|
2020-05-27 09:47:01 | Alnylam's ALNY Lumasiran NDA Gets Priority Review From FDA
2020-05-26 16:00:00 | Alnylam to Webcast Presentations at Upcoming June Investor Conferences
2020-05-25 11:30:03 | Is Alnylam Pharmaceuticals ALNY Outperforming Other Medical Stocks This Year?
2020-05-21 07:03:00 | Is Alnylam Pharmaceuticals a Buy?
2020-05-11 10:46:02 | How Alnylam ALNY Stock Stands Out in a Strong Industry
2020-05-11 08:00:00 | Alnylam to Webcast Presentations at Upcoming May Investor Conferences
2020-05-07 12:00:04 | What Makes Alnylam ALNY a New Buy Stock
2020-05-07 11:30:03 | Is Alnylam Pharmaceuticals ALNY Outperforming Other Medical Stocks This Year?
2020-05-07 10:25:02 | Alnylam ALNY Beats on Q1 Earnings, Cuts Onpattro Sales View
2020-05-06 19:46:42 | Edited Transcript of ALNY earnings conference call or presentation 6-May-20 12:30pm GMT
2020-05-06 18:30:53 | Alnylam Pharmaceuticals Inc ALNY Q1 2020 Earnings Call Transcript
2020-05-06 13:27:00 | Alnylam Pharmaceuticals Lowers 2020 Sales Expectations Due to COVID-19
2020-05-06 09:25:01 | Alnylam Pharmaceuticals ALNY Reports Q1 Loss, Tops Revenue Estimates
2020-05-05 11:45:03 | Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
2020-05-05 11:40:03 | 5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
2020-05-05 10:40:02 | Is a Surprise Coming for Alnylam Pharmaceuticals ALNY This Earnings Season?
2020-05-04 10:23:00 | Vir Biotechnology and Alnylam Pick a Coronavirus Vaccine Candidate to Pursue
2020-05-04 08:24:57 | Vir, Alnylam identify COVID-19 therapy candidate, plan human trials by year end
2020-05-04 07:46:11 | Vir, Alnylam pick coronavirus therapy candidate, plan human trials by year end
2020-04-29 12:34:04 | Alnylam Pharmaceuticals ALNY Expected to Beat Earnings Estimates: Should You Buy?
2020-04-23 08:00:00 | Alnylam to Webcast Conference Call Discussing First Quarter 2020 Financial Results
2020-04-17 16:23:00 | Blackstone’s Byron Wien Weighs In on Employment, China, and the Health-Care System
2020-04-16 06:35:12 | These Mass. companies are developing COVID-19 treatments and tests
2020-04-15 11:15:03 | Alnylam's Vutrisiran Gets Fast Track Tag for hATTR Amyloidosis
2020-04-14 10:06:02 | Alnylam's $2B Deal With Blackstone to Boost Drug Development
2020-04-13 16:00:00 | Alnylam to Webcast Presentation at 19th Annual Needham Virtual Healthcare Conference
2020-04-13 14:57:56 | Alnylam plans Cambridge expansion after $2B investment
2020-04-13 07:46:00 | Blackstone invests $2 billion in Alnylam, boosting gene-silencing drug development
2020-04-13 07:43:00 | Alnylam Rises on $2 Billion Blackstone Investment
2020-04-13 07:41:52 | Blackstone invests $2 bln in Alnylam Pharma
2020-04-13 07:35:00 | Alnylam's stock surges after Blackstone confirms $2 billion investment
2020-04-13 01:23:59 | Blackstone/Alnylam: royalty flush
2020-04-09 08:00:19 | Is Pfizer Stock A Buy As It Partners On A Potential Coronavirus Vaccine?
2020-04-08 11:19:47 | Vir Biotech Adds Glaxo to List of Covid-19 Partners
2020-04-08 10:24:02 | Alnylam ALNY Completes Rolling Submission of Lumasiran NDA
2020-04-08 10:05:02 | Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
2020-04-07 07:00:00 | Alnylam Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration and Submits Marketing Authorization Application to the European Medicines Agency for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1
2020-04-06 18:26:17 | Alnylam, Dicerna Join Forces to Take on Arrowhead
2020-04-06 10:30:48 | Former gene-silencing rivals bury the hatchet with new partnership
2020-04-06 07:00:00 | Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs